Innovair Nexthaler

Beclometasone dipropionate / Formoterol fumarate, the active ingredient in Innovair Nexthaler, is an inhaled corticosteroid/long‑acting beta2‑agonist combination presented as a dry powder inhaler for inhalation use. It provides maintenance therapy for asthma and chronic obstructive pulmonary disease in adults and adolescents.

GNH USA supplies Innovair Nexthaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Innovair Nexthaler is used in the respiratory disease pathway to provide long‑term control of airway obstruction.

- Asthma: reduces symptoms, improves lung function and lowers the risk of exacerbations in patients with persistent asthma. - COPD: improves airflow, decreases symptom burden and helps prevent COPD exacerbations. - Chronic bronchitis (as part of COPD): maintains airway patency and reduces cough frequency.

Common Side Effects: - Throat irritation or soreness - Hoarseness of voice - Oral candidiasis (thrush) - Cough or wheeze after inhalation - Headache - Tremor or shakiness

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reaction (anaphylaxis) - Cardiovascular events such as tachycardia or arrhythmia - Hypokalemia (low blood potassium) - Hyperglycemia in diabetic patients

Precautions should be observed when prescribing Innovair Nexthaler. - Assess infection risk: monitor for respiratory infections before and during therapy. - Oral hygiene: rinse mouth after each inhalation to reduce candidiasis. - Cardiovascular caution: use carefully in patients with known heart disease or arrhythmias. - Avoid abrupt discontinuation: taper under medical supervision to prevent loss of control. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Potential drug interactions must be considered.

Major Interactions (Avoid): - Non‑selective beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase systemic steroid exposure.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate hypokalemia when combined with beta2‑agonists. - Other inhaled corticosteroids: increase risk of systemic effects. - CYP3A4 inducers (e.g., rifampicin): may reduce steroid efficacy. - Anticholinergic bronchodilators: monitor for additive anticholinergic effects.